Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.

• 2025.12.11

  • News Release

  Approval of Clinical Research Protocol for 64Cu-PD-29875, a Claudin 18.2-Targeting Radiopharmaceutical, in Patients with Gastric Cancer（PeptiDream Inc.）

• 2025.12.05

  R&D Briefing Materials (December 5, 2025)（PeptiDream Inc.）

• 2025.11.25

  • News Release

  PeptiDream Submits IND Applications for Phase 1 Clinical Trials of 225Ac-PD-32766 and 64Cu-PD-32766 in Patients with Kidney Cancer（PeptiDream Inc.）

• 2025.11.19

  • Information

  Upcoming Conference Presentation at RSNA2025

• 2025.11.06

  • Information

  PDRadiopharma to Present and Exhibit at the 65th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine and the 45th Annual Meeting of the Japanese Society of Nuclear Medicine Technology

• 2025.10.15

  • News Release

  PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

• 2025.10.01

  • Information

  Upcoming Conference Presentation at EANM’25（PeptiDream Inc.）

• 2025.09.25

  • News Release

  Launch of “onti dandori” – A Scheduling Module for the “onti” System for Nuclear Medicine Exposure Dose Management

• 2025.09.19

  • News Release

  Bridgea DISPENSER Now Equipped with Liquid Collection Function — Enhancing Operational Efficiency and Safety in Radiopharmaceutical Preparation

• 2025.09.19

  • News Release

  PDRadiopharma Receives Approval for Expanded Indication of Raiatt MIBG-I131 for Neuroblastoma